BSE Live
Mar 20, 16:01Prev. Close
161.30
Open Price
161.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:58Prev. Close
161.41
Open Price
162.33
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
170.05 (110)
| Cash Flow of Marksans Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 0.63 | 2.39 | 19.27 | 9.56 | 31.32 | |
| Net CashFlow From Operating Activities | 11.61 | 89.27 | -25.49 | -28.40 | 13.61 | |
| Net Cash Used In Investing Activities | -33.89 | -141.56 | -69.44 | -14.11 | -28.19 | |
| Net Cash Used From Financing Activities | 41.78 | 22.10 | -20.33 | 3.36 | 202.37 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 19.50 | -30.19 | -115.25 | -39.16 | 187.79 | |
| Cash And Cash Equivalents Begin of Year | 13.01 | 43.20 | 158.45 | 197.61 | 9.51 | |
| Cash And Cash Equivalents End Of Year | 32.51 | 13.01 | 43.20 | 158.45 | 197.30 |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth